The next generation biopharmaceuticals

Affibody AB and Biotest AG enter into a Research License and Option Agreement regarding the Albumod™ platform

2015-06-01

Dreieich, Germany and Solna, Sweden – Biotest AG and Affibody AB today announced that the companies have signed a Research License and Option Agreement.

The agreement relates to the use of Affibody’s proprietary Albumod™ platform, which is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, with compounds from Biotest’s portfolio of proprietary molecules.

Affibody’s CEO, David Bejker, said: “Biotest with their vast experience in development of protein based drugs is an ideal partner for our Albumod™ platform and we are very pleased to announce this agreement today. This announcement further illustrates that our license driven business model can continue to deliver new collaborations”.

Affibody will receive up-front and milestone payments as well as royalties on sales for licensing of the Albumod™ platform. Further details of the agreement have not been disclosed.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daiichi-Sankyo, Daewoong, Nordic Nanovector, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Year-end report (February 24, 2017)